Polyrizon PLRZ

Polyrizon Ltd. is a development stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays that form a thin hydrogel based shield containment barrier in the nasal cavity to block viruses and allergens from contacting the nasal epithelial tissue. The company also pursues a separate platform technology called T&T that is designed to enable sustained release of active pharmaceutical ingredients through intranasal delivery.

As a pre commercial entity Polyrizon Ltd. generates revenue primarily from licensing agreements, milestone payments, and research collaborations. The SciSparc License Agreement provides potential milestone payments of up to $3.32 million and royalties on net sales while agreements with Clearmind Medicine and Eurofins support further development and may generate future income.

The company operates through the following segments: Capture and Contain (C&C) and Trap and Target (T&T).

• Capture and Contain (C&C): This segment focuses on developing hydrogel nasal sprays that create a physical barrier against viruses and allergens in the nasal cavity.

• Trap and Target (T&T): This segment focuses on creating hydrogel formulations that enable sustained release of active pharmaceutical ingredients for intranasal delivery of drugs such as corticosteroids, benzodiazepines, naloxone, and pain therapeutics.

Polyrizon Ltd. occupies a niche in the nasal drug delivery and medical device markets where its proprietary hydrogel technology differentiates it from larger pharmaceutical companies. Competitors in the barrier segment include Alzair Nasalease and Bentrio while companies such as Sanofi GlaxoSmithKline Merck and Teva dominate the intranasal corticosteroid space. The firm’s competitive advantages stem from its tunable mucoadhesive polymers strong intellectual property portfolio and collaborations with academic institutions and industry partners.

Polyrizon Ltd. serves pharmaceutical companies seeking nasal drug delivery partners healthcare providers and patients who suffer from allergies viral infections pain or opioid overdose. While the filing does not disclose specific customer names the company’s development stage focus indicates that its primary contacts are research collaborators licensing partners and potential future distributors.